SCHEMBL1099376

SCHEMBL1099376

Cc1c(N(CCC(F)(F)F)S(=O)(=O)c2ccc(-c3nnn[nH]3)cc2)sc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 14/20 0.44
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
RORC P51449 1/20 0.34
KEAP1 Q14145 1/20 0.32
NFE2L2 Q16236 1/20 0.32
NR1H2 P55055 1/20 0.32
PFKFB3 Q16875 1/20 0.30
HTR1A P08908 1/20 0.30
DRD2 P14416 1/20 0.30
HTR2A P28223 1/20 0.30
HTR7 P34969 1/20 0.30
HTR6 P50406 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1098956 0.90 ESR1 (0.36) TRPM8ESR1ESR2RORCKEAP1
SCHEMBL1099455 0.89 RORC (0.36) TRPM8ESR1ESR2RORCKEAP1
SCHEMBL1099489 0.87 TRPM8 (0.40) TRPM8ESR1HTR1ADRD2HTR2A
SCHEMBL1097814 0.86 TRPM8 (0.40) TRPM8HTR1ADRD2HTR2AHTR7
SCHEMBL1097914 0.84 TRPM8 (0.43) TRPM8ESR1ESR2RORCNR1H2
SCHEMBL1099908 0.84 TRPM8 (0.33) TRPM8ESR1ESR2KEAP1NFE2L2
SCHEMBL13963096 0.83 TRPM8 (0.40) TRPM8ESR1ESR2KEAP1NFE2L2
SCHEMBL1100499 0.83 TRPM8 (0.53) TRPM8ESR1ESR2RORCNR1H2
SCHEMBL1098344 0.83 TRPM8 (0.45) TRPM8ESR1ESR2RORC
SCHEMBL1098824 0.83 TRPM8 (0.33) TRPM8ESR1ESR2RORCKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885ESR1 1247/4885ESR2 946/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885ESR1 1247/4885ESR2 946/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TRPM8 1/4885ESR1 1247/4885ESR2 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.